Cargando…

Disturbing the Redox Balance Using Buthionine Sulfoximine Radiosensitized Somatostatin Receptor-2 Expressing Pre-Clinical Models to Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE

SIMPLE SUMMARY: Peptide receptor radionuclide therapy with (177)Lu-DOTATATE is an efficient treatment for patients suffering from metastasized neuroendocrine tumours. Nevertheless, suboptimal effects have been observed in the majority of patients. Hence, strategies to improve (177)Lu-DOTATATE effica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Delbart, Wendy, Marin, Gwennaëlle, Stamatopoulos, Basile, de Wind, Roland, Sirtaine, Nicolas, Demetter, Pieter, Vercruyssen, Marie, Woff, Erwin, Karfis, Ioannis, Ghanem, Ghanem E., Flamen, Patrick, Wimana, Zéna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137255/ https://www.ncbi.nlm.nih.gov/pubmed/37190261 http://dx.doi.org/10.3390/cancers15082332

Ejemplares similares

Understanding the Radiobiological Mechanisms Induced by (177)Lu-DOTATATE in Comparison to External Beam Radiation Therapy
por: Delbart, Wendy, et al.
Publicado: (2022)

Accuracy and precision assessment for activity quantification in individualized dosimetry of (177)Lu-DOTATATE therapy
por: Marin, Gwennaëlle, et al.
Publicado: (2017)

Everolimus-induced somatostatin receptor overexpression in a rectal neuroendocrine tumor patient may promote somatostatin receptor-guided radionuclide therapy (peptide receptor radiotherapy) as an additional treatment option
por: Mileva, Magdalena, et al.
Publicado: (2020)

Suspicious cold thyroid nodule with intense focal 68Ga-DOTATATE uptake: a case report
por: Manta, Ringo, et al.
Publicado: (2022)

Practical kidney dosimetry in peptide receptor radionuclide therapy using [(177)Lu]Lu-DOTATOC and [(177)Lu]Lu-DOTATATE with focus on uncertainty estimates
por: Staanum, Peter Frøhlich, et al.
Publicado: (2021)

Lutetium Lu-177 Dotatate Flare Reaction
por: Salner, Andrew L., et al.
Publicado: (2020)

Depletion of tumour versus normal tissue glutathione by buthionine sulfoximine.
por: Lee, F. Y., et al.
Publicado: (1987)

l-Buthionine Sulfoximine Detection and Quantification in Polyurea Dendrimer Nanoformulations
por: Mota, Pedro, et al.
Publicado: (2019)

Effects of Buthionine Sulfoximine Treatment on Cellular Glutathione Levels and Cytotoxicities of Cisplatin, Carboplatin and Radiation in Human Stomach and Ovarian Cancer Cell Lines(*): – Glutathione, Buthionine Sulfoximine, Cytotoxicity –
por: Lee, Kyung Shik, et al.
Publicado: (1992)

Nifurtimox Is Effective Against Neural Tumor Cells and Is Synergistic with Buthionine Sulfoximine
por: Du, Michael, et al.
Publicado: (2016)

Peptide Receptor Radionuclide Therapy With (177)Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome
por: Zandee, Wouter T, et al.
Publicado: (2021)

(90)Y/(177)Lu-DOTATATE therapy: survival of the fittest?
por: Brans, Boudewijn, et al.
Publicado: (2011)

Concomitant (177)Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
por: Yadav, Madhav Prasad, et al.
Publicado: (2019)

(177)Lu-DOTATATE therapy in metastatic/inoperable pheochromocytoma-paraganglioma
por: Kumar Jaiswal, Sanjeet, et al.
Publicado: (2020)

Tissue dose estimation after extravasation of (177)Lu-DOTATATE
por: Tylski, Perrine, et al.
Publicado: (2021)

Efficacy of (177)Lu-Dotatate Therapy in the Treatment of Recurrent Meningioma
por: Zahid, Anza, et al.
Publicado: (2021)

Combined effect of buthionine sulfoximine and cyclophosphamide upon murine tumours and bone marrow.
por: Ono, K., et al.
Publicado: (1986)

In vivo production of different chloroform metabolites: effect of phenobarbital and buthionine sulfoximine pretreatment.
por: Gemma, S, et al.
Publicado: (1994)

The responses of Ht22 cells to oxidative stress induced by buthionine sulfoximine (BSO)
por: Chen, Jun, et al.
Publicado: (2005)

Somatostatin receptor saturation after administration of high peptide amounts of [(177)Lu]Lu-HA-DOTATATE: when enough is enough
por: Siebinga, Hinke, et al.
Publicado: (2022)

Radiation precautions for inpatient and outpatient (177)Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
por: Levart, D., et al.
Publicado: (2019)

A Clinical Guide to Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE in Neuroendocrine Tumor Patients
por: Becx, Morticia N., et al.
Publicado: (2022)

Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with (177)Lu-DOTATATE
por: Vyakaranam, Achyut Ram, et al.
Publicado: (2019)

Repurposed Effect of (177)Lu-DOTATATE in the Treatment of Mantle Cell Lymphoma
por: Elajami, Mohamad K., et al.
Publicado: (2022)

3-bromopyruvate and buthionine sulfoximine effectively kill anoikis-resistant hepatocellular carcinoma cells
por: Lee, Minjong, et al.
Publicado: (2017)

Comparison of commercial dosimetric software platforms in patients treated with (177)Lu‐DOTATATE for peptide receptor radionuclide therapy
por: Mora‐Ramirez, Erick, et al.
Publicado: (2020)

Upregulation of Somatostatin Receptor Type 2 Improves (177)Lu-DOTATATE Therapy in Receptor-Deficient Pancreatic Neuroendocrine Tumor Model
por: Sharma, Rupali, et al.
Publicado: (2023)

The Safety and Efficacy of the Repeated PRRT with [(90)Y]Y/[(177)Lu]Lu-DOTATATE in Patients with NET
por: Zemczak, Anna, et al.
Publicado: (2021)

Individualised (177)Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
por: Sundlöv, Anna, et al.
Publicado: (2017)

Imaging DNA Damage Repair In Vivo After (177)Lu-DOTATATE Therapy
por: O’Neill, Edward, et al.
Publicado: (2020)

Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with (177)Lu-DOTATATE
por: Strosberg, Jonathan R., et al.
Publicado: (2021)

p53-Mediated Radiosensitization of (177)Lu-DOTATATE in Neuroblastoma Tumor Spheroids
por: Lundsten, Sara, et al.
Publicado: (2021)

Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis
por: Lewis-Wambi, Joan S, et al.
Publicado: (2008)

Enhancement of Antitumor Activity of Cisplatin on Human Gastric Cancer Cells in vitro and in vivo by Buthionine Sulfoximine
por: Saikawa, Yoshiro, et al.
Publicado: (1993)

A Care Process Model to Deliver (177)Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2019)

(177)Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Metastatic or Advanced and Inoperable Primary Neuroendocrine Tumors of Rare Sites
por: Thapa, Pradeep, et al.
Publicado: (2017)

Outcome analysis in patients with metastatic gastroenteropancreatic neuroendocrine tumors receiving peptide receptor radionuclide therapy with Lu-177-DOTATATE
por: Prétot, Dominique, et al.
Publicado: (2023)

Impact of cyclic changes in pharmacokinetics and absorbed dose in pediatric neuroblastoma patients receiving [(177)Lu]Lu-DOTATATE
por: Malcolm, Javian C., et al.
Publicado: (2022)

Efficacy of [(177)Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study
por: Mitjavila, Mercedes, et al.
Publicado: (2023)

Evaluation of (177)Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors
por: Abou Jokh Casas, Estephany, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2dt32srk010jsbkddlctg59inu